RxDoctor Payments Data

Erica Combs, APRN

Family · Wichita, KSNPI 1609292168

Payments from drug & device makers

$1,527in general payments, 2019–2025

Across 36 payments — averaging $42.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$263
  • Abbott$238
  • Alnylam Pharmaceuticals Inc.$220
  • AstraZeneca$171
  • Novo Nordisk$141
  • Actelion Pharmaceuticals US, Inc.$99
  • plus $396 from 8 others

What the payments were for

  • Food & beverage$1,520100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,527 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$54,394
Medicare patients
234
Services billed
903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$49,584
EntrestoSacubitril/Valsartan18$19,754
Nitroglycerin PatchNitroglycerin27$1,103
Nifedipine ErNifedipine40$773
Bumetanide50$542
Losartan Potassium89$513
Nitroglycerin33$444
Potassium Chloride46$430
Amiodarone Hcl25$428
ClopidogrelClopidogrel Bisulfate32$331
Amlodipine Besylate95$318
Metoprolol Succinate14$292
Torsemide26$281
Furosemide59$271
Hydralazine Hcl14$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$49,58460 claims
NovartisEntresto$77$19,75418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.

Other family in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →